subject: Pwrm.ob, Alny, & Xprt: Aic And Cpi Successfully Deliver New Crime Information System For The State O [print this page] POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)
PWRM is now available for $0.038 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:
Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets
The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance.
Continue your research at www.power3medical.com
________________________________________________
Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY)
Recent News: AIC and CPI Successfully Deliver New Crime Information System for the State of Colorado
Alnylam Pharmaceuticals Inc. is a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data are being presented at the ASCO meeting in a poster titled Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement, in the Developmental Therapeutics Experimental Therapeutics poster session being held from 8:00 a.m. to 12:00 p.m. CT in S Hall A2. The study results from the initial 19 patients in the first four dose cohorts demonstrate that ALN-VSP is well tolerated in most patients, and results from pharmacodynamic measurements provide preliminary evidence of clinical activity. The study has not yet reached a maximum tolerated dose and is continuing enrollment with dose escalation.
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the worlds top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics for the treatment of a wide range of disease areas, including respiratory syncytial virus (RSV), liver cancers, TTR-mediated amyloidosis (ATTR), hypercholesterolemia, and Huntingtons disease. In addition, Alnylam formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.
Visit: http://www.alnylam.com
________________________________________________
LECG Corporation - (NASDAQ:XPRT) provides independent expert testimony and original authoritative studies in adversarial and non-adversarial environments to corporations and law firms, as well as local, state, and federal governments and agencies in the United States and internationally. The company conducts economic, financial, accounting, and statistical analyses to provide objective opinions and strategic advice to legislative, judicial, regulatory, and business decision makers.
*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
